Compare ADMA Biologics Inc (ADMA) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Avantis US Small Cap Value ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Avantis US Small Cap Value ETF trades at $127.9. The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AVUV | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $128.74 |
52-Week Low | $7.60 | $93.93 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
AVUV trades at $126.88, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights strong small-cap value performance and potential benefits from rate outlook shifts. The ETF focuses on U.S. small-cap value stocks, offering diversification from tech-heavy portfolios.
Outlook remains positive due to small-cap momentum and value factor tailwinds, but risks include higher volatility and sensitivity to interest rates. Analyst sentiment is favorable, emphasizing long-term growth potential in tax-advantaged accounts like Roth IRAs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
